pds01adc
pds01adc: developed by 1 company · 2 clinical trials tracked.
pds01adc evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could pds01adc → PDSB affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 2 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| PDS Biotechnology Corp (PDSB) Metastatic castration sensitive and castration resistant pro… | Phase 2 |
Clinical Trials (2)
Phase II Trial of Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
Primary endpoint: Determine if the combination of enzalutamide and PDS01ADC is associated with an increase in the duration of PSA suppression compared to that of enzalutamide alone
Phase II Study Evaluating the Efficacy of PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Primary endpoint: Determine overall response rates
Frequently asked questions
Who is developing pds01adc?
pds01adc is being developed by PDS Biotechnology Corp.
How many clinical trials involve pds01adc?
BioSniper tracks 2 clinical trials involving pds01adc.